[18F]Fluorodeoxyglucose (INN), or fluorodeoxyglucose F 18 (USAN and USP), also commonly called fluorodeoxyglucose and abbreviated [18F]FDG, 2- [18F]FDG or FDG, is a radiopharmaceutical, specifically a radiotracer, used in the medical imaging modality positron emission tomography (PET).

Aug 28, 2023 · Fludeoxyglucose F18 (FDG) is a positron-emitting radiotracer used with positron emission tomography (PET) to diagnose and monitor various conditions. Standard imaging modalities such as X-ray, CT, and MRI allow great detail visualization of …

Sep 27, 2024 · The U.S. Food and Drug Administration (FDA) has granted a long-awaited approval to flurpiridaz F-18, GE HealthCare's first-of-its-kind positron emission tomography (PET) myocardial perfusion imaging radiotracer, for the detection of coronary artery disease (CAD).

18 F-FDG PET/CT is more sensitive and specific in certain cancers and has been applied primarily as a staging and restaging tool that can guide patient care. It has also been used to distinguish responders from nonresponders before any reduction in tumor size occurs.

Apr 1, 2025 · Fludeoxyglucose F 18 injection is used to help diagnose cancer, heart disease, and epilepsy. It is used in a procedure called a positron emission tomography (PET) scan to help your doctor see parts of the body, such as the heart or brain.

Fludeoxyglucose F 18 Injection (fdg) is a positron emitting radiopharmaceutical used for diagnostic imaging purposes in conjunction with Positron Emission Tomography (PET). It is also used to help assess cancer, coronary artery disease, or epileptic seizures.

Mar 26, 2025 · F-18 fluorodeoxyglucose (FDG) is the most common PET radiotracer. The radiopharmaceutical consists of the fluorine-18 radionuclide substituting the hydroxyl group at the C-2 position of glucose. The IUPAC chemical name is 2-deoxy-2- [F-18]fluoroglucose.

F-18 FDG-PET/CT plays an important role in staging and re-staging of high-risk melanoma (AJCC Stages III and IV). In addition, in patients with cutaneous melanoma PET/CT is useful for initial staging, evaluation of treatment response, recurrence detection, and prognosis of the disease.

Oct 7, 2024 · Fluorodopa F 18 Injection is a radioactive diagnostic agent indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS).

Reston, VA (September 30, 2024) - The U.S. Food and Drug Administration (FDA) has approved flurpiridaz F-18 (Flyrcado; GE Healthcare), a first-of-its-kind positron emission tomography (PET) imaging agent, for use in adult patients with known or suspected coronary artery disease (CAD).